77. Psychiatric Genetics: Methods and Reviews, edited by Marion Leboyer and Frank Bellivier, 2003
75. Lung Cancer: Volume 2, Diagnostic and Therapeutic Methods and Reviews, edited by Barbara Driscoll, 2003
74. Lung Cancer: Volume 1, Molecular Pathology Methods and Reviews, edited by Barbara Driscoll, 2003
73. E. coli: Shiga Toxin Methods and Protocols, edited by Dana Philpott and Frank Ebel, 2003
72. Malaria Methods and Protocols, edited by Denise L. Doolan, 2002
64. Dendritic Cell Protocols, edited by Stephen P. Robinson and Andrew J. Stagg, 2001
50. Colorectal Cancer: Methods and Protocols, edited by Steven M. Powell, 2001
Preface

This work, *Lung Cancer, Volume 2: Diagnostic and Therapeutic Methods and Reviews*, in the *Methods in Molecular Medicine* series presents an overview of the current status of those methods useful in the diagnosis and treatment of lung cancer—both as it exists in the clinic and as it is being revolutionized in the laboratory. The book is intended to serve as a resource for researchers wishing to increase their knowledge of current and cutting edge technologies, in order that their investigations into neoplasms of the lung may benefit from this enriched diversity of techniques and approaches.

Owing to the complex nature of the disease and the variety of methods available to analyze and attack it, no volume attempting to define diagnostic and therapeutic approaches to lung cancer can ever be complete. The sheer number of investigators involved in lung cancer research guarantees that some aspect will be inadvertently excluded. However, I hope that the range of techniques included herein will serve to open up new avenues of investigation for both the novice and experienced researcher.

As with all volumes in the *Methods in Molecular Medicine* series, the reader should find that each methods-based chapter provides clear instructions for the performance of various protocols, supplemented by additional technical notes that provide valuable insight. These notes should offer the reader a perspective on the skills and materials required for performance of both standard and novel techniques. In putting together this volume, one aim was to provide clinicians and laboratory investigators an appreciation of the current status of lung cancer diagnosis and treatment. However, *Lung Cancer, vol. 2* is also a look into the future, with descriptions of novel methods for molecular diagnosis as well as techniques for treatment based on gene therapies, new anticancer approaches, immune therapies, and chemoprevention. Chapters describing the challenges faced by those attempting to employ these new methods should also be of use to those determined to translate basic research from the laboratory to the clinic.

I would like to express my gratitude to the contributors who made this volume possible and for their patience during the period the volume was collated. I am grateful to Professor John Walker for his encouragement and guidance as series editor.

This volume is dedicated to the memory of Richard Mackenzie Brown, Warren Reardon, and Ching-Tuan T’Ang, three fathers, deeply missed.

*Barbara Driscoll, PhD*
Contents

Preface ................................................................................................................................. v

Contents of Volume I ........................................................................................................... xiii

Contributors ..................................................................................................................... xvii

PART I. INTRODUCTION

1分子和遗传学方面 肺癌
William N. Rom and Kam-Meng Tchou-Wong ......................................................... 3

PART II. DETECTION OF ALTERED TUMOR MARKERS IN CLINICAL SAMPLES FOR DIAGNOSIS AND PROGNOSIS

A. MOLECULAR METHODS FOR PROGNOSTIC DETECTION OF ALTERED TUMOR MARKERS: CLINICAL IMPLICATIONS

2 Molecular Alterations in Lung Cancer: Impact on Prognosis
Takashi Kijima, Gautam Maulik, and Ravi Salgia ......................................................... 29

3 Cellular Predictive Factors of Drug Resistance in Non-Small Cell Lung Carcinomas
Manfred Volm, Reet Koomägi, and Werner Rittgen ...................................................... 39

4 Clinical Implications of p53 Mutations in Lung Cancer
Barbara G. Campling and Wafik S. El-Deiry ................................................................. 53

5 An Epidemiologic and Clinicopathologic Overview of AIDS-Associated Pulmonary Kaposi’s Sarcoma
David M. Aboulafia ........................................................................................................ 79

6 Myeloperoxidase Promoter Region Polymorphism and Lung Cancer Risk
Xifeng Wu, Matthew B. Schabath, and Margaret R. Spitz ........................................ 121

7 Clinical Utility of Tumor Markers in the Management of Non-Small Cell Lung Cancer
Dennis E. Niewoehner and Jeffrey B. Rubins .............................................................. 135

vii
<table>
<thead>
<tr>
<th>B. MOLECULAR METHODS FOR PROGNOSTIC DETECTION OF ALTERED LUNG TUMOR MARKERS IN CLINICAL SAMPLES</th>
</tr>
</thead>
<tbody>
<tr>
<td>I. DNA-Based Analysis \hline</td>
</tr>
<tr>
<td>8 Detection of Chromosomal Aberrations in Lung Tissue and Peripheral Blood Lymphocytes Using Interphase Fluorescence In Situ Hybridization (FISH) \hline</td>
</tr>
<tr>
<td>Randa A. El-Zein and Sherif Z. Abdel-Rahman \hline</td>
</tr>
<tr>
<td>9 In Situ Analysis of Telomerase RNA Gene Expression as a Marker for Tumor Progression \hline</td>
</tr>
<tr>
<td>W. Nicol Keith \hline</td>
</tr>
<tr>
<td>10 A High-Throughput Methodology for Identifying Molecular Targets Overexpressed in Lung Cancers \hline</td>
</tr>
<tr>
<td>Tongtong Wang and Steven G. Reed \hline</td>
</tr>
<tr>
<td>11 Expression Profiling of Lung Cancer Based on Suppression Subtraction Hybridization (SSH) \hline</td>
</tr>
<tr>
<td>Simone Petersen and Iver Petersen \hline</td>
</tr>
<tr>
<td>12 Comparative Genomic Hybridization of Human Lung Cancer \hline</td>
</tr>
<tr>
<td>Iver Petersen \hline</td>
</tr>
<tr>
<td>13 Sensitive Assays for Detection of Lung Cancer: Molecular Markers in Blood Samples \hline</td>
</tr>
<tr>
<td>Marcia V. Fournier, Katherine J. Martin, Edgard Graner, and Arthur B. Pardee \hline</td>
</tr>
<tr>
<td>14 Fluorescent Microsatellite Analysis in Bronchial Lavage as a Potential Diagnostic Tool for Lung Cancer \hline</td>
</tr>
<tr>
<td>John K. Field and Triantafillos Liloglou \hline</td>
</tr>
<tr>
<td>15 Southern Blotting of Genomic DNA from Lung and Its Tumors: Application to Analysis of Allele Loss on Chromosome 11p15.5 \hline</td>
</tr>
<tr>
<td>Diana M. Pitterle and Gerold Bepler \hline</td>
</tr>
<tr>
<td>16 Assessment of Insulin-Like Growth Factors and Mutagen Sensitivity as Predictors of Lung Cancer Risk \hline</td>
</tr>
<tr>
<td>Xifeng Wu, He Yu, Nimisha Makan, and Margaret R. Spitz \hline</td>
</tr>
<tr>
<td>II. PCR-Based Analyses \hline</td>
</tr>
<tr>
<td>17 Comparative Multiplex PCR and Allele-Specific Expression Analysis in Human Lung Cancer: Tools to Facilitate Target Identification \hline</td>
</tr>
<tr>
<td>Jim Heighway, Daniel Betticher, Teresa Knapp, and Paul Hoban \hline</td>
</tr>
<tr>
<td>18 Detection of K-ras Point Mutations in Sputum from Patients with Adenocarcinoma of the Lung by Point-EXACCT \hline</td>
</tr>
<tr>
<td>Veerle A. M. C. Somers and Frederick B. J. M. Thunnissen \hline</td>
</tr>
</tbody>
</table>
19 Detection of K-ras and p53 Mutations by “Mutant-Enriched” PCR-RFLP
Marcus Schuermann ................................................................. 325

20 Detection of Small Cell Lung Cancer by RT-PCR for Neuropeptides, Neuropeptide Receptors, or a Splice Variant of the Neuron Restrictive Silencer Factor
Judy M. Coulson, Samreen I. Ahmed, John P. Quinn, and Penella J. Woll ................................................................. 335

III. Immunohistochemical Analyses
21 Utilization of Thyroid Transcription Factor-1 Immunostaining in the Diagnosis of Lung Tumors
Nelson G. Ordoñez ........................................................................ 355

22 Molecular Biologic Substaining of Stage I NSCLC Through Immunohistochemistry Performed on Formalin-Fixed, Paraffin-Embedded Tissue
Mary-Beth Moore Joshi, Thomas A. D’Amico, and David H. Harpole, Jr. ........................................................................ 369

23 A Sensitive Immunofluorescence Assay for Detection of p53 Protein in the Sputum
Zumei Feng, Defa Tian, and Radoslav Goldman ........................... 389

24 SPR1: An Early Molecular Marker for Bronchial Carcinogenesis Derick Lau, Linlang Guo, Andrew Chan, and Reen Wu ................ 397

25 Determination of Biological Parameters on Fine-Needle Aspirates from Non-Small Cell Lung Cancer
Cecilia Bozzetti, Annamaria Guazzi, Rita Nizzoli, Nadia Naldi, Vittorio Franciosi, and Stefano Cascinu .................................... 405

IV. Imaging Analysis
26 Detection and Analysis of Lung Cancer Cells from Body Fluids Using a Rare Event Imaging System
Stine-Kathrein Kraeft, Ravi Salgia, and Lan Bo Chen .................. 423

27 Reconstruction of Geno-Phenotypic Evolutionary Sequences from Intracellular Patterns of Molecular Abnormalities in Human Solid Tumors
Stanley E. Shackney, Charles A. Smith, Agnese A. Pollice, and Jan F. Silverman ................................................................. 431

PART III. NOVEL THERAPIES
A. INTRODUCTION TO CURRENT TREATMENTS

28 Surgical Treatment of Lung Cancer: Past and Present
Clifton F. Mountain and Kay E. Hermes ........................................ 453
Contents

29 Recent Advances and Dilemmas in the Radiotherapeutic Management of Locally Advanced Non-Small Cell Lung Cancer
   Benjamin Movsas ................................................................. 489

30 Photodynamic Therapy in Lung Cancer: A Review
   David Ost ................................................................................. 507

B. GENE THERAPIES

I. Overview: Advantages and Pitfalls of Lung-Targeted Gene Therapies

31 Gene Therapy for Lung Cancer: An Introduction
   Eric B. Haura, Eduardo Sotomayor, and Scott J. Antonia ............. 529

32 Identifying Obstacles to Viral Gene Therapy for Lung Cancer: Malignant Pleural Effusions as a Paradigm
   Raj K. Batra, Raymond M. Bernal, and Sherven Sharma ............. 545

33 Topical Gene Therapy for Pulmonary Diseases with PEI-DNA Aerosol Complexes

II. Plasmid and Virus-Based Gene Therapies

34 Targeted Delivery of Expression Plasmids to the Lung via Macroaggregated Polyethylenimine-Albumin Conjugates

35 Preparation of Retroviral Vectors for Cell-Cycle-Targeted Gene Therapy of Lung Cancer
   Pier Paolo Claudio and Antonio Giordano .................................. 591

36 Aerosol Gene Therapy for Metastatic Lung Cancer Using PEI-p53 Complexes
   Ajay Gautam, J. Clifford Waldrep, Eugenie S. Kleinerman, Bo Xu, Yuen-Kai Fung, Anne T’Ang, and Charles L. Densmore .......................................................... 607

III. Antisense Oligonucleotide Gene Therapies

37 Clinical Development of Antisense Oligonucleotides as Anti-Cancer Therapeutics
   Helen X. Chen ........................................................................... 621

38 Antisense Oligonucleotides Targeting Rlα Subunit of Protein Kinase A: In Vitro and In Vivo Anti-Tumor Activity and Pharmacokinetics
   Ruiwen Zhang and Hui Wang .................................................... 637
Use of Antisense Oligonucleotides for Therapy: Manipulation of Apoptosis Inhibitors for Destruction of Lung Cancer Cells

Siân H. Leech, Robert A. Olie, and Uwe Zangemeister-Wittke

Induction of Programmed Cell Death with an Antisense Bcl-2 Oligonucleotide

Patrick P. Koty, Wendong Lei, and Mark L. Levitt

C. IMMUNE THERAPIES

Tumor Vaccination with Cytokine-Encapsulated Microspheres

Nejat K. Egilmez, Yong S. Jong, Edith Mathiowitz, and Richard B. Bankert

Adoptive Immunotherapy

Julian A. Kim and Suyu Shu

Intratumoral Therapy with Cytokine Gene-Modified Dendritic Cells in Murine Lung Cancer Models

Sherven Sharma, Seok Chul Yang, Raj K. Batra, and Steven M. Dubinett

Cyclooxygenase 2-Dependent Regulation of Antitumor Immunity in Lung Cancer

Sherven Sharma, Min Huang, Mariam Dohadwala, Mehis Pold, Raj K. Batra, and Steven M. Dubinett

D. CHEMOPREVENTION

Chemoprevention of Lung Cancer

Hanspeter Witschi

Assessing the Interaction of Particulate Delivery Systems with Lung Surfactant

Timothy Scott Wiedmann

Chemopreventive Therapeutics: Inhalation Therapies for Lung Cancer and Bronchial Premalignancy

Missak Haigentz, Jr. and Roman Perez-Soler

Index
CONTENTS OF THE COMPANION VOLUME

Lung Cancer

Volume I: Molecular Pathology Methods and Reviews

PART I. INTRODUCTION
1 Characteristic Genetic Alterations in Lung Cancer
   Ignacio I. Wistuba and Adi F. Gazdar

PART II. ETIOLOGY AND CLASSIFICATION OF LUNG TUMORS
2 Clinical and Biological Relevance of Recently Defined Categories of Pulmonary Neoplasia
   Edward Gabrielson
3 Molecular Epidemiology of Human Cancer Risk: Gene–Environment Interactions and p53 Mutation Spectrum in Human Lung Cancer
   Kirsi Vähäkangas
4 Neuroendocrine Phenotype of Small Cell Lung Cancer
   Judy M. Coulson, Marta Ocejo-Garcia, and Penella J. Woll
5 AIDS-Associated Pulmonary Cancers
   Kushagra Katariya and Richard J. Thurer

PART III. MOLECULAR ABNORMALITIES IN LUNG CANCER

A. DETECTION OF ALTERATIONS IN THE CELL CYCLE
6 Abrogation of the RB-p16 Tumor Suppressor Pathway in Human Lung Cancer
   Joseph Geradts
7 Sensitive Detection of Hypermethylated p16^{INK4a} Alleles in Exfoliative Tissue Material
   Marcus Schuermann and Michael Kersting

B. DETECTION OF ALTERATIONS IN SIGNAL TRANSDUCTION PATHWAYS
8 Role of Receptor Tyrosine Kinases in Lung Cancer
   Gautam Maulik, Takashi Kijima, and Ravi Salgia
9 Relationship of EGFR Signal-Transduction Modulation by Tyrosine Kinase Inhibitors to Chemosensitivity and Programmed Cell Death in Lung Cancer Cell Lines
   Wendong Lei, Patrick P. Koty, and Mark L. Levitt
10 Detection of the Transcripts and Proteins for the Transforming Growth Factor-β Isoforms and Receptors in Mouse Lung Tumorigenesis Using In Situ Hybridization and Immunohistochemistry in Paraffin-Embedded Tissue Sections
   Sonia B. Jakowlew and Jennifer Mariano
11 Alterations in the Expression of Insulin-Like Growth Factors and Their Binding Proteins in Lung Cancer
Carrie M. Coleman and Adda Grimberg

12 Screening of Mutations in the ras Family of Oncogenes by Polymerase Chain Reaction-Based Ligase Chain Reaction
Alfredo Martínez, Teresa A. Lehman, Rama Modali, and James L. Mulshine

13 Assays for Raf-1 Kinase Phosphorylation and Activity in Human Small Cell Lung Cancer Cells
Rajani K. Ravi and Barry D. Nelkin

14 γ-Glutamylcysteine Synthetase in Lung Cancer: Effect on Cell Viability
Kristiina Järvinen, Ylermi Soini, and Vuokko L. Kinnula

15 Localization of Cyclooxygenase-2 Protein Expression in Lung Cancer Specimens by Immunohistochemical Analysis
Sarah A. Wardlaw and Thomas H. March

16 Non-RI Protocols for L-myc Allelotyping and Deletion Mapping of Chromosome 1p in Primary Lung Cancers
Keiko Hiyama, Ciro Mendoza, and Eiso Hiyama

C. DETECTION OF ALTERED CELL SURFACE MARKERS
17 Intercellular Adhesion Molecules (ICAM-1, VCAM-1, and LFA-1) in Adenocarcinoma of Lung: Technical Aspects
Armando E. Fraire, Bruce A. Woda, Louis Savas, and Zhong Jiang

18 MUC1 Expression in Lung Cancer
Eva Szabo

19 Altered Surface Markers in Lung Cancer: Lack of Cell-Surface Fas/APO-1 Expression in Pulmonary Adenocarcinoma May Allow Escape from Immune Surveillance
Yoshihiro Nambu and David G. Beer

D. DETECTION OF ALTERATIONS IN THE APOPTOTIC PATHWAY
20 Prognostic Relevance of Angiogenic, Proliferative, and Apoptotic Factors in Lung Carcinomas: A Case Review
Manfred Volm and Reet Koomägi

21 Morphological Assessment of Apoptosis in Human Lung Cells
Lori D. Dwyer-Nield, David Dinsdale, J. John Cohen, Margaret K. T. Squier, and Alvin M. Malkinson
22 [D-Arg⁶, D-Trp⁷,⁹, N⁶mePhe⁸]-Substance P (6-11) Activates JNK and Induces Apoptosis in Small Cell Lung Cancer Cells via an Oxidant-Dependent Mechanism
   Alison MacKinnon and Tariq Sethi

23 Isolation of Cells Entering Different Programmed Cell Death Pathways Using a Discontinuous Percoll Gradient
   Patrick P. Koty, Haifan Zhang, Wendong Lei, and Mark L. Levitt

E. Detection of Alterations in Lung Cell-Directed Angiogenesis

24 Angiogenesis, Metastasis, and Lung Cancer: An Overview
   Amir Onn and Roy S. Herbst

25 Matrix Metalloproteinase Expression in Lung Cancer
   Melissa Lim and David M. Jablons

26 Vascular Endothelial Growth Factor Expression in Non-Small Cell Lung Cancer
   Kenneth J. O’Byrne, Jonathan Goddard, Alexandra Giatromanolaki, and Michael I. Koukourakis

27 Regulation of Angiostatin Mobilization by Tumor-Derived Matrix Metalloproteinase-2
   Marsha A. Moses and Michael S. O’Reilly

28 In Vitro and In Vivo Assays for the Proliferative and Vascular Permeabilization Activities of Vascular Endothelial Growth Factor (VEGF) and Its Receptor
   Seiji Yano, Roy S. Herbst, and Saburo Sone

F. Detection of Alterations in DNA Replication and Repair

29 Detection of Telomerase Activity in Lung Cancer Tissues
   Keiko Hiyama and Eiso Hiyama

30 Analysis of Alterations in a Base-Excision Repair Gene in Lung Cancer
   Nandan Bhattacharyya and Sipra Banerjee

PART IV. Lung Cancer Model Systems

A. Animal Models for Lung Cancer

31 Induction of Lung Cancer by Passive Smoking in an Animal Model System
   Hanspeter Witschi

32 Metastatic Orthotopic Mouse Models of Lung Cancer
   Robert M. Hoffman
33 Lung-Specific Expression of Mutant p53 as a Mouse Model for Lung Cancer

Kam-Meng Tchou-Wong and William N. Rom

34 Use of Nucleotide Excision Repair-Deficient Mice as a Model for Chemically Induced Lung Cancer

David L. Cheo and Errol C. Friedberg

B. ANIMAL MODELS FOR TUMOR METASTASES TO THE LUNG

35 Nude Mouse Lung Metastases Models of Osteosarcoma and Ewing’s Sarcoma for Evaluating New Therapeutic Strategies

Shu-Fang Jia, Rong-Rong Zhou, and Eugenie S. Kleinerman

36 Tumor-Specific Metastasis to Lung Using Reporter Gene-Tagged Tumor Cells

Lloyd A. Culp, Wen-Chang Lin, Nanette Kleinman, Julianne L. Holleran, and Carson J. Miller

C. MODELS FOR DEVELOPMENT OF TARGETED THERAPEUTICS

37 Cultures of Surgical Material from Lung Cancers: A Kinetic Approach

Bruce C. Baguley, Elaine S. Marshall, and Timothy I. Christmas

38 The Hollow Fiber Assay

Leslie-Ann M. Hall, Candice M. Krauthauser, Roseanne S. Wexler, Andrew M. Slee, and Janet S. Kerr
Contributors

SHERIF Z. ABDEL-RAHMAN • Department of Preventive Medicine and Community Health, The University of Texas Medical Branch, Galveston, TX

DAVID M. ABOULAFIA • Virginia Mason Clinic, Division of Hematology/Oncology, University of Washington, Seattle, WA

SAMREEN I. AHMED • Department of Medical Oncology, Weston Park Hospital, Sheffield, UK

SCOTT J. ANTONIA • H. Lee Moffitt Cancer Center, Tampa, FL

RICHARD B. BANKERT • Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY

MICHAEL A. BARRY • Departments of Microbiology and Immunology and Molecular and Human Genetics, Baylor College of Medicine, Houston, TX

RAJ K. BATRA • Wadsworth Pulmonary Immunology Laboratory, Veterans Administration Greater Los Angeles Healthcare System; Division of Pulmonary and Critical Care Medicine, University of California at Los Angeles School of Medicine, Los Angeles, CA

GEROLD BEpler • H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

RAYMOND M. BERNAL • Division of Pulmonary and Critical Care Medicine, UCLA School of Medicine, and Veterans Administration Greater Los Angeles Health Care System, Los Angeles, CA

DANIEL BETTICHER • Department of Clinical Research, Institute of Medical Oncology, University of Bern, Switzerland

BALBIR S. BHOGAL • Veterans Affairs Medical Center and Department of Internal Medicine, Baylor College of Medicine, Houston TX

CECILIA BOZZETTI • Divisione di Oncologia Medica, Azienda Ospedaliera-Universitaria di Parma, Parma, Italy

BARBARA G. CAMPLING • Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute; Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA

STEFANO CASCINU • Divisione di Oncologia Medica, Azienda Ospedaliera-Universitaria di Parma, Parma, Italy
Contributors

Andrew Chan • Division of Pulmonary Medicine; Division of Hematology/Oncology, University of California, Davis Cancer Center, Sacramento, CA

Helen X. Chen • Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD

Lan Bo Chen • Department of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA

Pier Paolo Claudio • Department of Biotechnology, Temple University, Philadelphia, PA

Judy M. Coulson • Departments of Physiology and Human Anatomy, University of Liverpool, Liverpool, UK

Thomas A. D’Amico • Thoracic Oncology Program, Duke University Medical Center, Durham, NC

Charles L. Densmore • Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX

Mariam Dohadwala • Wadsworth Pulmonary Immunology Laboratory, Veterans Administration Greater Los Angeles Healthcare System; University of California Los Angeles School of Medicine, Los Angeles, CA

Steven M. Dubinett • Wadsworth Pulmonary Immunology Laboratory, Veterans Administration Greater Los Angeles Healthcare System; Jonsson Comprehensive Cancer Center and Division of Pulmonary and Critical Care Medicine, University of California Los Angeles School of Medicine, Los Angeles, CA

Nejat K. Egilmez • Department of Microbiology, State University of New York, Buffalo, NY

Wafik S. El-Deiry • Laboratory of Molecular Oncology and Cell Cycle Regulation, Howard Hughes Medical Institute, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA

Randa A. El-Zein • Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

Zumei Feng • Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC

John K. Field • Roy Castle International Centre for Lung Cancer Research and Molecular Genetics & Oncology Group, Clinical Dental Sciences, The University of Liverpool, Liverpool, UK

Marcia V. Fournier • Adult Oncology Division, Dana-Farber Cancer Institute, Boston, MA

Vittorio Franciosi • Divisione di Oncologia Medica, Azienda Ospedaliera-Universitaria di Parma, Parma, Italy
YUEN-KAI FUNG • Divisions of Hematology/Oncology and Ophthalmology, Childrens Hospital Los Angeles Research Institute, and Departments of Pediatrics, Microbiology and Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, CA

AJAY GAUTAM • Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX

ANTONIO GIORDANO • Department of Biotechnology, Temple University, Philadelphia, PA

RADOSLAV GOLDMAN • Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC

EDGARD GRANER • Dana-Farber Cancer Institute, Department of Adult Oncology, Boston, MA

ANNAMARIA GUZZI • Divisione di Oncologia Medica, Azienda Ospedaliera-Universitaria di Parma, Parma, Italy

LINLANG GUO • Division of Hematology/Oncology, University of California Davis Cancer Center, Sacramento, CA

MISSAK HAIGENTZ, JR. • Division of Medical Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY

DAVID H. HARPOLE, JR. • Thoracic Oncology Program, Duke University Medical Center, Durham, NC

ERIC B. HAURA • H. Lee Moffitt Cancer Center, Tampa, FL

JIM HEIGHWAY • Roy Castle International Centre for Lung Cancer Research, Liverpool, UK

KAY E. HERMES • Clifton F. Mountain Foundation, Houston, TX

PAUL HOBAN • Centre for Cell and Molecular Medicine, Keele University School of Postgraduate University, North Staffordshire Hospital, Stoke-on-Trent, UK

MIN HUANG • Wadsworth Pulmonary Immunology Laboratory, Veterans Administration Greater Los Angeles Healthcare System, University of California Los Angeles School of Medicine, Los Angeles, CA

YONG S. JONG • Department of Molecular Pharmacology, Physiology and Biotechnology, Brown University, Providence, RI

W. NICOL KEITH • CRC Department of Medical Oncology and CRC Beatson Laboratories, University of Glasgow, Glasgow, UK

TAKASHI KIJIMA • Division of Adult Oncology and Thoracic Oncology Program, Department of Medicine, Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

JULIAN A. KIM • Center for Surgery Research, Cleveland Clinic, Cleveland, OH
BERMA M. KINSEY • Veterans Affairs Medical Center and Department of Internal Medicine, Baylor College of Medicine, Houston, TX
EUGENIE S. KLEINERMAN • Department of Pediatrics, The University of Texas M. D. Anderson Cancer Center, Houston, TX
TERESA KNAPP • Roy Castle International Centre For Lung Cancer Research, Liverpool, UK
REET KOOMÄGI • Department of Oncological Diagnostics and Therapy, Central Unit of Biostatistics, German Cancer Research Center, Heidelberg, Germany
PATRICK P. KOTY • Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA
STINE-KATHERIN KRAEFT • Department of Cancer Biology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
DERICK LAU • Division of Pulmonary Medicine; Division of Hematology/Oncology, University of California, Davis Cancer Center, Sacramento, CA
SIAN H. LEECH • School of Biological Sciences, The University of Manchester, Manchester, UK
WENDONG LEI • Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
MARK L. LEVITT • Department of Environmental and Occupational Health, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA; Sheba Medical Center, Institute of Oncology, Tel Hashomer, Israel
TRIANTAFILLOS LIOLOGLOU • Roy Castle International Centre for Lung Cancer Research and Molecular Genetics & Oncology Group, Clinical Dental Sciences, The University of Liverpool, UK
NIMISHA MAKAN • Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
KATHERINE J. MARTIN • Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA
EDITH MATHIOWITZ • Department of Molecular Pharmacology, Physiology and Biotechnology, Brown University, Providence, RI
GAUTAM MAULIK • Division of Adult Oncology and Thoracic Oncology Program, Department of Medicine, Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
MARY-BETH MOORE JOSHI • Thoracic Oncology Program, Duke University Medical Center, Durham, NC
CLIFTON F. MOUNTAIN • Division of Cardiothoracic Surgery, The University of California at San Diego, San Diego, CA
Contributors

WERNER RITTGEN • Department of Oncological Diagnostics and Therapy, Central Unit of Biostatistics, German Cancer Research Center, Heidelberg, Germany

WILLIAM N. ROM • Bellevue Chest Service, NYU Medical Center and Division of Pulmonary and Critical Care Medicine, Department of Medicine, NYU School of Medicine, New York, NY

JEFFREY B. RUBINS • Pulmonary Section, Veterans Affairs Medical Center, University of Minnesota, Minneapolis, MN

RAVI SALGIA • Division of Adult Oncology and Thoracic Oncology Program, Department of Medicine, Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

MATTHEW B. SCHABATH • Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX

MARCUS SCHUERMANN • Department of Hematology, Oncology and Immunology, Phillipps-University of Marburg, Marburg, Germany

STANLEY E. SHACKNEY • Laboratory of Cancer Cell Biology and Genetics, Department of Human Oncology and Human Genetics, MCP/Hahnemann University, Allegheny General Hospital, Pittsburgh, PA

SHERVEN SHARMA • Wadsworth Pulmonary Immunology Laboratory, Veterans Administration Greater Los Angeles Healthcare System, University of California Los Angeles School of Medicine, Los Angeles, CA

SUYU SHU • Center for Surgery Research, Cleveland Clinic, Cleveland, OH

JAN F. SILVERMAN • Department of Pathology and Laboratory Medicine, MCP/Hahnemann University, Allegheny General Hospital, Pittsburgh, PA

CHARLES A. SMITH • Laboratory of Cancer Cell Biology and Genetics, Department of Human Oncology, MCP/Hahnemann University, Allegheny General Hospital, Pittsburgh, PA

VEERLE A. M. C. SOMERS • Department of Pathology, Maastricht University Hospital, Maastricht, The Netherlands

LING SONG • Department of Internal Medicine, Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX

EDUARDO SOTOMAYOR • H. Lee Moffitt Cancer Center & Research Institute, University of South Florida, Tampa, FL

MARGARET R. SPITZ • Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX

ANNE T’ANG • Division of Hematology/Oncology and Department of Pathology, Childrens Hospital Los Angeles Research Institute; Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA
KAM-MENG TCHOU-WONG • Division of Pulmonary and Critical Care Medicine, Department of Medicine, NYU School of Medicine, New York, NY
FREDERICK B. J. M. THUNNISSEN • Department of Pathology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
DEFA TIAN • Department of Oncology, Lombardi Cancer Center, Georgetown University Medical Center, Washington, DC
MANFRED VOLM • Department of Oncological Diagnostics and Therapy, Central Unit of Biostatistics, German Cancer Research Center, Heidelberg, Germany
J. CLIFFORD WALDREP • Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX
HUI WANG • Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, University of Alabama at Birmingham, Birmingham, AL
TONGTONG WANG • Department of Tumor Antigen Discovery, Corixa Corporation, Seattle, WA
TIMOTHY SCOTT WIEDMANN • Department of Pharmaceutics, University of Minnesota, Minneapolis, MN
HANSPIETER WITSCHI • CHE and Department of Molecular Biosciences, School of Veterinary Medicine, University of California, Davis, CA
PENELLA J. WOLL • FRCP Department of Clinical Oncology, University of Nottingham, Nottingham, UK
REEN WU • Division of Pulmonary Medicine and Division of Hematology/Oncology, University of California, Davis Cancer Center, Sacramento, CA
XIFENG WU • Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX
BO XU • Department of Molecular Physiology and Biophysics, Baylor College of Medicine, Houston, TX
SEOK CHUL YANG • Wadsworth Pulmonary Immunology Laboratory, Veterans Administration Greater Los Angeles Healthcare System, Los Angeles, CA
HE YU • Section of Cancer Prevention and Control, Feist-Weiller Cancer Center, Louisiana State University Medical Center, Shreveport, LA
UWE ZANGEMEISTER-WITTKE • Division of Medical Oncology, Department of Internal Medicine, University Hospital Zurich, Zurich, Switzerland
RUIWEN ZHANG • Division of Clinical Pharmacology, Department of Pharmacology and Toxicology, Comprehensive Cancer Center, and Gene Therapy Center, University of Alabama at Birmingham, Birmingham, AL